Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
High-fat and high-carbohydrate diets increase bone fragility through TGF-β–dependent control of osteocyte function
Neha S. Dole, Andrés Betancourt-Torres, Serra Kaya, Yoshihiro Obata, Charles A. Schurman, Jihee Yoon, Cristal S. Yee, Vivek Khanal, Clarissa Aguirre Luna, Madeline Carroll, Jennifer J. Salinas, Elizabeth Miclau, Claire Acevedo, Tamara Alliston
Neha S. Dole, Andrés Betancourt-Torres, Serra Kaya, Yoshihiro Obata, Charles A. Schurman, Jihee Yoon, Cristal S. Yee, Vivek Khanal, Clarissa Aguirre Luna, Madeline Carroll, Jennifer J. Salinas, Elizabeth Miclau, Claire Acevedo, Tamara Alliston
View: Text | PDF
Research Article Bone biology

High-fat and high-carbohydrate diets increase bone fragility through TGF-β–dependent control of osteocyte function

  • Text
  • PDF
Abstract

Obesity can increase the risk of bone fragility, even when bone mass is intact. This fragility stems from poor bone quality, potentially caused by deficiencies in bone matrix material properties. However, cellular and molecular mechanisms leading to obesity-related bone fragility are not fully understood. Using male mouse models of obesity, we discovered TGF-β signaling plays a critical role in mediating the effects of obesity on bone. High-carbohydrate and high-fat diets increase TGF-β signaling in osteocytes, which impairs their mitochondrial function, increases cellular senescence, and compromises perilacunar/canalicular remodeling and bone quality. By specifically inhibiting TGF-β signaling in mouse osteocytes, some of the negative effects of high-fat and high-carbohydrate diets on bones, including the lacunocanalicular network, perilacunar/canalicular remodeling, senescence, and mechanical properties such as yield stress, were mitigated. DMP1-Cre–mediated deletion of TGF-β receptor II also blunted adverse effects of high-fat and high-carbohydrate diets on energy balance and metabolism. These findings suggest osteocytes are key in controlling bone quality in response to high-fat and high-carbohydrate diets. Calibrating osteocyte function could mitigate bone fragility associated with metabolic diseases while reestablishing energy balance.

Authors

Neha S. Dole, Andrés Betancourt-Torres, Serra Kaya, Yoshihiro Obata, Charles A. Schurman, Jihee Yoon, Cristal S. Yee, Vivek Khanal, Clarissa Aguirre Luna, Madeline Carroll, Jennifer J. Salinas, Elizabeth Miclau, Claire Acevedo, Tamara Alliston

×

Figure 3

Hyperglycemia and hyperlipidemia affect osteocyte intrinsic cellular metabolism.

Options: View larger image (or click on image) Download as PowerPoint
Hyperglycemia and hyperlipidemia affect osteocyte intrinsic cellular met...
Undifferentiated OCY454 cells were exposed to hyperlipidemia (HF, palmitate 100 μm, oleate 200 μm, linoleate-200 μm) or hyperglycemia (HG, glucose 25 mM) in the presence or absence of TGF-β (5 ng/mL) or TGF-β receptor I kinase inhibitor, SB431542 (10 μM), for 24 hours. In response to HF, HG, and TGF-β treatment, changes in oxygen consumption rate (OCR) parameters, namely, ATP production (A and E) and maximum respiration (B and F), were measured. Changes in intracellular ROS with HF (C and D) and HG (G and H) treatment determined with DCFDA stain have been quantified as mean fluorescence intensity (MFI) (N = 3 technical replicates/condition). Changes in mitochondrial membrane potential (I and J) with JC1 dye with TGF-β, HFG (palmitate, oleate, linoleate, glucose), or a combination of both treatments were quantified as red-to-green fluorescence intensity ratios (R/G) from sum projections, then normalized to the control group (for I, scale bar is 5 μm; for J, N = 3 technical replicates/condition). Changes in OCR parameters, namely, maximum respiration (K and M) and ATP production (L and N) in HF-, HG-, and SB431542-treated OCY454 cells have been shown. (N = 5 technical replicates/condition.) For A–N, data are presented as mean ± SD and were reproduced across 3 independent experiments. *P < 0.05 different from the untreated group, #P < 0.05 different from the TGF-β–treated group, $P < 0.05 different from HF- or HG-treated groups, and differences were calculated with 2-way ANOVA and Newman-Keuls multiple post hoc correction. Statistical interactions are provided in Supplemental Tables 3 and 4.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts